Pfizer Settles Long-Running Cancer Research IP Suit

Pfizer Inc. has reached a settlement with AntiCancer Inc. to resolve claims the drug giant unlawfully terminated a patent licensing agreement for AntiCancer's research technology following Pfizer's 2009 merger with fellow pharmaceutical behemoth Wyeth.

Rate this item
(0 votes)
Login to post comments

Newsletter Subscription

Joomla forms builder by JoomlaShine

IP2017 Banner 380x280

IP Era 300x250

Go to top